Dr Mark Socinski analyzes data from the CITYSCAPE and COAST studies showing improved ORR and PFS with combinations of novel immunotherapy agents in patients with metastatic or locally advanced/unresectable NSCLC, and from the CheckMate-743 study, in which the combination of nivolumab plus ipilimumab resulted in improved survival over chemotherapy in patients with malignant pleural mesothelioma.
